OBJECTIVE: To identify predictors of initial sputum culture conversion, estimate the usefulness of persistent positive cultures at different time points in predicting treatment failure, and evaluate different definitions of culture conversion for predicting failure among patients with multidrug-resistant tuberculosis (MDR-TB) in five countries, 2000-2004. METHODS: Predictors of time to conversion were identified using multivariate Cox proportional hazards regression modeling. Receiver operating characteristic curves were plotted to visualize the effect of using different definitions of 'culture conversion' on the balance between sensitivity and specificity. RESULTS: Overall, 1209/1416 (85%) of patients with baseline positive cultures converted in a median of 3.0 months (interquartile range 2.0-5.0). Independent predictors of less likely conversion included baseline positive smear (hazard ratio [HR] 0.60, 95%CI 0.53-0.68), resistance to pyrazinamide (HR 0.82, 95%CI 0.70-0.96), fluoroquinolones (FQs; HR 0.65, 95%CI 0.51-0.83) or thioamide (HR 0.83, 95%CI 0.71-0.96), previous use of FQs (HR 0.71, 95%CI 0.60-0.83), poor outcome of previous anti-tuberculosis treatment (HR 0.69, 95%CI 0.54-0.88) and alcoholism (HR 0.74, 95%CI 0.63-0.87). The maximum combined sensitivity (84%) and specificity (94%) in predicting treatment failure was based on lack of culture conversion at month 9 of treatment, assuming conversion is defined as five consecutive negative cultures. CONCLUSION: Patients with identified risk factors were less likely to achieve sputum culture conversion during MDR-TB treatment.
OBJECTIVE: To identify predictors of initial sputum culture conversion, estimate the usefulness of persistent positive cultures at different time points in predicting treatment failure, and evaluate different definitions of culture conversion for predicting failure among patients with multidrug-resistant tuberculosis (MDR-TB) in five countries, 2000-2004. METHODS: Predictors of time to conversion were identified using multivariate Cox proportional hazards regression modeling. Receiver operating characteristic curves were plotted to visualize the effect of using different definitions of 'culture conversion' on the balance between sensitivity and specificity. RESULTS: Overall, 1209/1416 (85%) of patients with baseline positive cultures converted in a median of 3.0 months (interquartile range 2.0-5.0). Independent predictors of less likely conversion included baseline positive smear (hazard ratio [HR] 0.60, 95%CI 0.53-0.68), resistance to pyrazinamide (HR 0.82, 95%CI 0.70-0.96), fluoroquinolones (FQs; HR 0.65, 95%CI 0.51-0.83) or thioamide (HR 0.83, 95%CI 0.71-0.96), previous use of FQs (HR 0.71, 95%CI 0.60-0.83), poor outcome of previous anti-tuberculosis treatment (HR 0.69, 95%CI 0.54-0.88) and alcoholism (HR 0.74, 95%CI 0.63-0.87). The maximum combined sensitivity (84%) and specificity (94%) in predicting treatment failure was based on lack of culture conversion at month 9 of treatment, assuming conversion is defined as five consecutive negative cultures. CONCLUSION:Patients with identified risk factors were less likely to achieve sputum culture conversion during MDR-TB treatment.
Authors: Jan Heyckendorf; Sophia B Georghiou; Nicole Frahm; Norbert Heinrich; Irina Kontsevaya; Maja Reimann; David Holtzman; Marjorie Imperial; Daniela M Cirillo; Stephen H Gillespie; Morten Ruhwald Journal: Clin Microbiol Rev Date: 2022-03-21 Impact factor: 50.129
Authors: Maia Kipiani; Veriko Mirtskhulava; Nestani Tukvadze; Matthew Magee; Henry M Blumberg; Russell R Kempker Journal: Clin Infect Dis Date: 2014-08-04 Impact factor: 9.079
Authors: Yì Xiáng J Wáng; Myung Jin Chung; Aliaksandr Skrahin; Alex Rosenthal; Andrei Gabrielian; Michael Tartakovsky Journal: Quant Imaging Med Surg Date: 2018-03
Authors: Dylan B Tierney; Molly F Franke; Mercedes C Becerra; Félix A Alcántara Virú; César A Bonilla; Epifanio Sánchez; Dalia Guerra; Maribel Muñoz; Karim Llaro; Eda Palacios; Lorena Mestanza; Rocío M Hurtado; Jennifer J Furin; Sonya Shin; Carole D Mitnick Journal: PLoS One Date: 2014-09-19 Impact factor: 3.240
Authors: Argita D Salindri; Maia Kipiani; Russell R Kempker; Neel R Gandhi; Lasha Darchia; Nestani Tukvadze; Henry M Blumberg; Matthew J Magee Journal: Open Forum Infect Dis Date: 2016-06-16 Impact factor: 3.835
Authors: Ekaterina V Kurbatova; J Peter Cegielski; Christian Lienhardt; Rattanawadee Akksilp; Jaime Bayona; Mercedes C Becerra; Janice Caoili; Carmen Contreras; Tracy Dalton; Manfred Danilovits; Olga V Demikhova; Julia Ershova; Victoria M Gammino; Irina Gelmanova; Charles M Heilig; Ruwen Jou; Boris Kazennyy; Salmaan Keshavjee; Hee Jin Kim; Kai Kliiman; Charlotte Kvasnovsky; Vaira Leimane; Carole D Mitnick; Imelda Quelapio; Vija Riekstina; Sarah E Smith; Thelma Tupasi; Martie van der Walt; Irina A Vasilyeva; Laura E Via; Piret Viiklepp; Grigory Volchenkov; Allison Taylor Walker; Melanie Wolfgang; Martin Yagui; Matteo Zignol Journal: Lancet Respir Med Date: 2015-02-26 Impact factor: 30.700
Authors: Matthew J Magee; Russell R Kempker; Maia Kipiani; Nestani Tukvadze; Penelope P Howards; K M Venkat Narayan; Henry M Blumberg Journal: PLoS One Date: 2014-04-15 Impact factor: 3.240